These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38385995)

  • 1. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
    Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
    Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
    Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
    Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
    Tian J; Lin Z; Chen Y; Fu Y; Ding Z
    Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
    Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
    Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.
    Liu Z; Li P; Wu Q; Zhou Q
    Asian J Surg; 2024 Apr; 47(4):1851-1852. PubMed ID: 38182507
    [No Abstract]   [Full Text] [Related]  

  • 7. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
    Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report.
    Wang Y; Yang X; Tian X; Jia Z; Bing Z; Cao L; Gao C; Cao Z; Li S; Liang N
    Ann Palliat Med; 2020 Nov; 9(6):4339-4345. PubMed ID: 33183013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.
    Zhang Y; Zhang H; Wang H; Zeng J; Zhang B; Zhou N; Zu L; Song Z; Wang C; Xu S
    Front Oncol; 2022; 12():968030. PubMed ID: 36176406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
    Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
    Front Oncol; 2022; 12():954886. PubMed ID: 36052259
    [No Abstract]   [Full Text] [Related]  

  • 11. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
    Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
    BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
    Ma P; Huang R; Gu Y; Fang Y; Wu X; Chen DS; Zhang HW; Gao W; Shu Y
    Anticancer Drugs; 2022 Nov; 33(10):1186-1190. PubMed ID: 35946569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
    Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
    Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
    Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
    J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection.
    Yang F; Chen QF
    Anticancer Drugs; 2023 Feb; 34(2):302-305. PubMed ID: 36730552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report.
    Tan X; Dai L; Wang Y; Liang G; Yang N; Chen M
    Medicine (Baltimore); 2017 Nov; 96(47):e8744. PubMed ID: 29381967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.